Verastem (VSTM)
(Delayed Data from NSDQ)
$11.50 USD
-0.63 (-5.19%)
Updated May 17, 2024 04:00 PM ET
After-Market: $11.48 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
VSTM 11.50 -0.63(-5.19%)
Will VSTM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VSTM
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
Other News for VSTM
Buy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
Buy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive Outlook
RBC Capital Sticks to Their Buy Rating for Verastem (VSTM)
Verastem Inc. Poised for Growth: Buy Rating Affirmed on Clinical and Regulatory Milestones